Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults
about
Immune mechanisms of protection: can adjuvants rise to the challenge?Influenza vaccination in HIV-positive subjects: latest evidence and future perspectiveInfluenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspectiveImmunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individualsDurability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports.Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.Aflunov(®): a prepandemic influenza vaccine.Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine.Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccineInfluenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responsesCross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccinesMF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.Correlates of vaccine protection from influenza and its complications.Cancer vaccine adjuvants--recent clinical progress and future perspectives.Vaccines for the prevention against the threat of MERS-CoV.Influenza vaccination in healthcare workers: A comprehensive critical appraisal of the literature.A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients.Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults i
P2860
Q21245319-25ED6198-945E-41EB-A8AC-967D171F8C19Q27007483-5FC8B1F5-9CBB-4B3D-80D2-82958A4BF545Q28740919-986DFAAF-232D-4820-B0DB-AE9FB5B03F0AQ30357158-BBF24483-47AE-43E8-B373-0014522A1041Q30362521-FFAFA6B4-DEFB-416B-BB81-464092B16F69Q30397400-67642631-B0A1-49F2-8333-15FCDB0F2232Q30400385-D412A60B-8C3A-4E94-AEE3-579B5658BD8BQ30401158-1809C0BA-86AE-4EA9-92B4-96176AA2ABC7Q30403299-1B873D7F-C271-4FEF-B33D-213BC00D3367Q30412595-5FAECB6A-A376-46BD-85A5-7C2CF1CB63E1Q30412628-1BA6B5B7-2DA0-4DD0-902A-2876DF81AD7FQ36552868-D6A34EDC-5244-4AAA-AEE9-EE4BCA3B07CDQ36737727-8A7E3D7D-63AC-403D-AE7F-7AD5CF76FD17Q37309289-74DE2B54-6029-41C9-A888-BED525EFBAB3Q37416103-948CCF0A-DCBF-4353-AFF8-D020803B4AEFQ37478319-6E59DCC7-B394-4A5E-B958-D65863210BC1Q37706610-B5822DB7-2999-4DB9-9987-509C8B764DF0Q37976539-5DB5A968-F3F3-4894-BE0E-FF5FEDB0BFE0Q38260496-8347A257-694F-447B-9E3C-9D41F5E62B3FQ38778044-1C19A36E-B9D5-450C-AD17-D517801AD963Q47749933-DE7A3C9A-0835-46D1-9C34-993BFE223455Q51065162-E28A2DCD-E5B9-4D8A-A672-1A3BE2A6EB41Q51831461-02523A58-C254-41C5-AFE8-C3E527997469Q57103712-B58AA5D0-1B37-4C74-9BEA-EB78412F570B
P2860
Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Safety and immunogenicity of t ...... itive and -seronegative adults
@ast
Safety and immunogenicity of t ...... itive and -seronegative adults
@en
type
label
Safety and immunogenicity of t ...... itive and -seronegative adults
@ast
Safety and immunogenicity of t ...... itive and -seronegative adults
@en
prefLabel
Safety and immunogenicity of t ...... itive and -seronegative adults
@ast
Safety and immunogenicity of t ...... itive and -seronegative adults
@en
P2093
P2860
P356
P1476
Safety and immunogenicity of t ...... itive and -seronegative adults
@en
P2093
A Boschini
B Bruzzone
E Fragapane
F Indiveri
G Del Giudice
P2860
P304
P356
10.1128/CVI.00316-07
P577
2007-11-14T00:00:00Z